Open AccessCase Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate–Severe Crohn’s Disease
Author(s) -
Scott D. Lee,
Kendra Kamp,
Kindra ClarkSnustad
Publication year - 2022
Publication title -
crohn s and colitis 360
Language(s) - English
Resource type - Journals
ISSN - 2631-827X
DOI - 10.1093/crocol/otac012
Subject(s) - ustekinumab , medicine , crohn's disease , adverse effect , gastroenterology , disease , population , infliximab , environmental health
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom